Valbenazine is a medication being studied to see how well it helps people with tardive dyskinesia (TD), a condition causing uncontrolled movements. This study will last up to 24 weeks and involves people who have conditions like schizophrenia, bipolar disorder, or major depressive disorder. Researchers want to find out how valbenazine can improve the quality of life for people with TD by looking at how patients and doctors report changes in health and daily activities.
To join, you need to be at least 18 years old and have a stable mental condition. However, if you have other significant movement issues or unstable health conditions, you might not be eligible. This study aims to help people with TD live better lives by assessing how effective valbenazine is in reducing symptoms.
NCT05859698
Neurocrine Biosciences
8 July 2024
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Congrats! You have your own personal workspace now.